Author

H. A. Yu

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

A. A. Jungbluth· 1 shared A. Chow· 1 shared A. D. Jayaprakash· 1 shared A. Quintanal-Villalonga· 1 shared B. Houck-Loomis· 1 shared C. A. Iacobuzio-Donahue· 1 shared C. M. Lovly· 1 shared C. M. Rudin· 1 shared

Activity by Year

2018-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. A. Jungbluth

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Multi-omic analysis of lung tumors defines pathways activated in neuroendocrine transformation

A. Quintanal-Villalonga, H. Taniguchi, M. A. Hasan, F. Meng, F. Uddin, M. Donoghue, H. H. Won, S. S. Chavan, J. M. Chan, M. Ciampricotti, A. Chow, M. Offin, J. C. Chang, J. Ray-Kirton, J. Egger, , T. Sen

The paper identifies molecular mechanisms of neuroendocrine transformation in lung cancer using multi-omic analysis of tumors and clinical samples.

bioRxiv · Dec 2, 2020 · PreprintCancer Biology

YES1 amplification: a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics

P.-D. Fan, G. Narzisi, A. D. Jayaprakash, E. Venturini, N. Robine, P. Smibert, S. Germer, H. A. Yu, E. J. Jordan, P. K. Paik, Y. Y. Janjigian, J. E. Chaft, L. Wang, A. A. Jungbluth, S. Middha, , M. Ladanyi

This study identifies YES1 amplification as a novel mechanism of resistance to EGFR inhibitors in lung cancer using transposon mutagenesis and clinical genomic analysis.

bioRxiv · Mar 17, 2018Cancer Biology